Enanta Pharmaceuticals (ENTA) Balance Sheet: Assets & Liabilities

Enanta Pharmaceuticals (ENTA) Balance Sheet

As of Sep 30, 2025 (end of fiscal 2025), Enanta Pharmaceuticals reported total assets of $280.73M and total liabilities of $216.01M. Shareholders' equity was $64.72M, down 49.8% from $128.81M a year earlier. Total debt stood at $85.47M against $188.86M in cash and short-term investments, a net cash position of $103.40M. That puts debt-to-equity at 1.32, compared with 0.69 a year earlier.

Enanta Pharmaceuticals Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Enanta Pharmaceuticals, Inc. (ENTA) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020	Sep 2019	Sep 2018	Sep 2017
Current Assets
Cash and Cash Equivalents	32.30	37.23	85.39	43.99	57.21	87.13	51.23	63.90	65.68
Short-Term Investments	156.57	210.95	284.52	205.24	186.80	299.52	284.01	244.83	157.99
Cash & Short-Term Investments	188.86	248.19	369.91	249.23	244.00	386.65	335.24	308.73	223.67
Accounts Receivable	6.88	6.65	39.62	20.32	60.83	23.49	51.31	67.21	10.61
Inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	8.59	12.41	13.26	13.45	14.19	26.70	15.30	8.91	7.07
Total Current Assets	204.34	299.85	422.79	311.71	319.02	436.84	401.85	380.39	237.82
Non-Current Assets
Property, Plant & Equipment (Net)	72.94	73.35	34.71	29.75	10.65	15.62	10.93	8.37	8.05
Long-Term Investments	3.36	3.36	3.97	29.29	109.02	33.24	65.01	16.39	70.04
Other Non-Current Assets	3.45	3.45	0.80	4.66	0.09	0.09	0.70	0.70	0.61
Total Non-Current Assets	76.40	76.80	39.48	63.70	121.84	53.95	87.98	33.84	88.82
Total Assets	280.73	376.65	462.28	375.41	440.86	490.79	489.83	414.23	326.64
Current Liabilities
Accounts Payable	1.95	8.00	4.10	6.00	9.54	5.74	6.69	4.75	3.71
Short-Term Debt	30.71	34.46	5.28	5.78	8.41	4.26	0.00	0.00	0.08
Current Portion of Long-Term Debt	30.71	34.46	35.08	-	-	-	-	-	-
Accrued Liabilities	12.75	13.55	18.34	20.94	22.43	-	-	-	-
Deferred Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	9.30
Other Current Liabilities	30.71	34.46	53.42	18.05	18.23	14.16	15.92	9.89	7.89
Total Current Liabilities	48.56	57.54	62.79	29.83	36.17	24.16	22.61	16.03	20.98
Non-Current Liabilities
Long-Term Debt	54.76	53.94	21.24	22.37	2.63	5.32	0.20	0.29	0.38
Deferred Tax Liabilities	0.00	0.00	0.00	5.18	2.07	4.66	1.75	1.79	1.18
Other Non-Current Liabilities	111.39	135.01	161.52	0.45	0.56	1.08	4.53	4.23	3.60
Total Non-Current Liabilities	167.46	190.30	182.75	24.25	5.26	11.05	4.73	4.52	3.98
Total Liabilities	216.02	247.84	245.54	54.08	41.43	35.21	27.34	20.55	24.96
Stockholders' Equity
Common Stock	0.21	0.21	0.21	0.21	0.20	0.20	0.20	0.19	0.19
Retained Earnings	-404.93	-323.04	-207.00	-73.18	48.58	127.57	163.74	117.36	45.36
Accumulated Other Comprehensive Income	-0.34	0.30	-1.17	-3.72	-0.38	0.84	0.15	-0.40	-0.11
Additional Paid-in Capital	469.77	451.34	424.69	398.03	351.03	326.96	298.41	276.53	256.24
Shares Outstanding	21.39	21.19	21.06	20.79	-	-	-	-	-
Total Stockholders' Equity	64.72	128.81	216.74	321.33	399.43	455.58	462.49	393.68	301.68
Total Liabilities & Equity	280.73	376.65	462.28	375.41	440.86	490.79	489.83	414.23	326.64

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Enanta Pharmaceuticals Balance Sheet

How much debt does Enanta Pharmaceuticals have?

Enanta Pharmaceuticals had total debt of $85.47M as of Sep 30, 2025, against $188.86M in cash and short-term investments. Its debt-to-equity ratio was 1.32. Total debt was $88.41M a year earlier.

What are Enanta Pharmaceuticals's total assets?

Enanta Pharmaceuticals reported total assets of $280.73M as of Sep 30, 2025, down 25.5% from $376.65M a year earlier. Total liabilities were $216.01M.

What is Enanta Pharmaceuticals's shareholders' equity?

Enanta Pharmaceuticals's shareholders' equity was $64.72M as of Sep 30, 2025, or about $3.03 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition